CTVA stock sentiment todayCorteva, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
CTVA
Corteva, Inc.Corteva is transforming from a legacy chemical player into a high-margin biotech powerhouse, driven by biologicals and royalty savings.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for CTVA. Not financial advice.
Price · last 12 months
Gossip
The narrative is centered on 'self-help' margin expansion. The market is cheering the shift away from paying royalties to Bayer (for Enlist technology) and the aggressive expansion into biologicals. Recent momentum is driven by a strong 2025 outlook and a massive $3 billion buyback authorization.
- ·Transition to Enlist E3 seed dominance
- ·Biologicals portfolio scaling faster than peers
- ·Significant EBITDA margin expansion targets through 2025
- ·Royalties turning from a cost into a revenue stream
Financial
Strong balance sheet with accelerating free cash flow. While sales volume has faced headwinds due to inventory destocking, pricing power remains robust. The company is successfully pivoting to a high-value seed and crop protection mix that commands premium pricing.
- ·Operating EBITDA margins trending toward 21-23%
- ·Significant $3B share repurchase program
- ·Low net debt-to-EBITDA ratio (<1.5x)
- ·Strong R&D spend at ~8% of sales
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Depressed farm income levels impacting grower spending
- ·Commodity price volatility (Corn/Soybeans)
- ·Regulatory hurdles for new pesticide registrations
- ·Foreign exchange headwinds in Latin American markets
Peer temperature
How direct competitors stack up against CTVA right now.
- COLDBAYRYBayer AG
COLDER — Burdened by massive litigation debt and structural glyphosate weakness while CTVA takes their seed market share.
See full analysis → - NEUTRALFMCFMC Corporation
COLDER — Higher leverage and more exposure to generic price competition in crop chemicals compared to CTVA's proprietary seed traits.
See full analysis → - NEUTRALNTRNutrien Ltd.
NEUTRAL — More dependent on volatile fertilizer commodity cycles rather than the high-margin, IP-protected biologicals driving CTVA's premium.
See full analysis →
- CTVA+12.3%
- BAYRY+0.7%
- FMC+22.5%
- NTR+21.7%
Analyst price target
Consensus average of 15 analysts · median 95.00
Source: StockAnalysis.com · updated 2026-08-28
AI-generated analysis for informational purposes only. Not financial advice.